US-based biopharmaceutical company Mirum Pharmaceuticals has reported positive findings from the Phase III RESTORE clinical trial of Chenodal (chenodiol) tablets to treat cerebrotendinous xanthomatosis (CTX).

The placebo-controlled, randomised withdrawal trial assessed the efficacy and safety of Chenodal in CTX patients in the US and Brazil.

Urine bile alcohols were among the secondary outcomes evaluated as part of the trial.

Study data from 13 adult patients showed that the treatment caused a ‘statistically significant’ decline in bile alcohols, meeting the primary endpoint.

At the end of the double-blind, randomised withdrawal period, Chenodal treatment reduced bile alcohols by 20 times more than the placebo.

Results also showed that the treatment improved serum cholestanol, which is a crucial factor associated with poor outcomes in patients. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In addition, a relatively higher proportion of subjects in the placebo needed blinded rescue therapy in the trial.

Diarrhoea and headaches were the most frequent adverse events linked to Chenodal in the trial.

Mirum Pharmaceuticals plans to file a new drug application for Chenodal with the US Food and Drug Administration (FDA) in the first half of next year.

Mirum Pharmaceuticals president and CEO Chris Peetz said: “The statistically significant reductions in bile alcohols and cholestanol underscore the potential for Chenodal to have a dramatic and meaningful impact on patients with CTX. 

“This is an extraordinary outcome and we look forward to moving quickly to submit these data to the FDA with the goal of broadening the impact of Chenodal for patients with CTX.”

Based in California, Mirum Pharmaceuticals aims to ‘transform’ the treatment of rare diseases affecting children and adults.

Earlier this year, the company enrolled patients in its Phase IIb EMBARK trial of Livmarli (maralixibat) in infants with biliary atresia following hepatoportoenterostomy.

The double-blind, placebo-controlled trial is assessing mean changes in total bilirubin as a primary endpoint.